Clinical Endocrinology · 2012 · 43 citations · 28 references
MedicineEndocrinologyInternal MedicineClinical EpidemiologyDiabetologyPediatric EndocrinologyDiabetes ManagementDiabetes MellitusAcromegaly SurgeryPituitary Adenoma SurgerySex Differences In DiabetesTertiary Care OrganizationTertiary CentersTreatment Outcome AnalysisTreatment Outcome MeasurementTreatment Outcome Prediction
OBJECTIVE: To evaluate demographic data and quality of care of patients with acromegaly in Canada and their evolution over time and secondly, to evaluate predictors of co-morbidities and treatment outcomes. DESIGN AND PATIENTS: Retrospective analyses of clinical, biochemical and treatment outcome data of 649 patients with acromegaly (males: 50·7%) followed from 1980 to 2010 (mean 10·2 years, SD 13·7) in eight tertiary care centres from six Canadian provinces. RESULTS: In comparison to 1980-1994, the number of patients referred with acromegaly in the last 15 years was higher with female preponderance (52·8% vs 41·4%, P = 0·01) and an older age at diagnosis (46·4 ± 14 vs 41·3 ± 12 years, P < 0·0001). Diabetes was present in 28%, hypertension in 37% and sleep apnoea in 33% of cases. Pretreatment IGF-1 levels, but not GH levels were significant predictors of diabetes (P = 0·0002) and hypertension (P < 0·0001). Eighty-nine per cent of patients underwent pituitary surgery, 64·5% had medical therapy and 22% received radiotherapy. Radiotherapy was less utilized in the past 15 years (16% vs 45%, P < 0·0001). Multimodal therapy achieved remission or control of acromegaly in 70% of patients. Patients in remission or disease control had lower initial random GH (P = 0·04) and IGF-1 levels (P < 0·0001). Hypopituitarism was present in 23% of patients and cancer in 8·5%. CONCLUSIONS: There was an increase over time of referral for acromegaly management with female predilection. Initial higher IGF-1, but not GH levels, were predictive of co-morbidities and persistent active disease after treatment. Disease remission or control was attained in 70% of patients utilizing multimodal therapy.
28
Edward L. Giovannucci, David M. Harlan, Michael C. Archer et al. · Diabetes Care · 2010 · 2.2K citations · Full text
Medicine, Cancer Biology, Oncology +14
Antonio Mestrón, R. Astorga, Pedro J. Benito et al. · European Journal of Endocrinology · 2004 · 387 citations
John Ayuk, Richard N. Clayton, G Holder et al. · The Journal of Clinical Endocrinology & Metabolism · 2004 · 346 citations · Full text
Medicine, Endocrinology, Surgery +17
John A. Jane, Robert M. Starke, Mohamed Elzoghby et al. · The Journal of Clinical Endocrinology & Metabolism · 2011 · 320 citations · Full text
Medicine, Endocrinology, Surgery +11